首页 | 本学科首页   官方微博 | 高级检索  
     

辛伐他汀对结直肠癌患者IL-6与IL-8血清表达及癌细胞分泌影响的研究
引用本文:包成梅,闫建伟,孙巧兰,李文跃. 辛伐他汀对结直肠癌患者IL-6与IL-8血清表达及癌细胞分泌影响的研究[J]. 中国现代普通外科进展, 2012, 15(9): 687-690
作者姓名:包成梅  闫建伟  孙巧兰  李文跃
作者单位:1. 济南市第二人民医院内科 山东 济南 250001
2. 济南市第二人民医院外科 山东 济南 250001
3. 山东大学齐鲁医院 急诊科 山东 济南 250012
4. 山东省德州市人民医院 肾内科 山东 德州 253014
摘    要:目的:研究辛伐他汀对结直肠癌患者IL-6及IL-8血清表达和癌细胞分泌的影响,初步探讨辛伐他汀在结直肠癌中的治疗机制。方法:应用ELISA检测结直肠癌患者与健康对照者血清中IL-6及IL-8水平,应用RT-PCR比较IL-6与IL-8在结直肠癌及癌旁组织的表达情况;应用ELISA检测结直肠癌患者辛伐他汀治疗后血清IL-6与IL-8的变化规律。应用ELISA检测辛伐他汀干预后结直肠癌细胞株(HT-29与Ca-co-2)上清中IL-6与IL-8变化。结果:结直肠癌患者血清IL-6与IL-8水平显著高于健康对照者(P<0.05)。IL-8 mRNA表达水平在癌组织明显高于癌旁组织(P<0.05);而IL-6 mRNA在癌组织与癌旁组织表达差异无统计学意义(P>0.05)。结肠癌患者应用辛伐他汀(80 mg/d)治疗14 d后,血清IL-6水平显著降低(P<0.05),而IL-8无明显变化(P>0.05)。应用浓度达到5μmol/L以上辛伐他汀干预结直肠癌细胞株HT-29与Caco-2后,其IL-6及IL-8分泌明显下降(P<0.05)。结论:辛伐他汀可以降低结直肠癌患者血清IL-6的水平,并可以抑制结直肠癌细胞IL-8与IL-6分泌。

关 键 词:辛伐他汀  结直肠肿瘤  IL-6  IL-8

Effect of simvastatin on IL-6 and IL-8 responses of colorectal cancer and cancer cells
BAO Cheng-mei , YAN Jian-wei , SUN Qiao-lan , LI Wen-yue. Effect of simvastatin on IL-6 and IL-8 responses of colorectal cancer and cancer cells[J]. Chinese Journal of Current Advances in General Surgery, 2012, 15(9): 687-690
Authors:BAO Cheng-mei    YAN Jian-wei    SUN Qiao-lan    LI Wen-yue
Affiliation:1Department of Internal Medicine,2Department of Surgery,Jinan Second People’s Hospital(Jinan 250001,China) 3Department of Emergency,Qilu Hospital of Shandong University(Jinan 250012,China) 4Department of Nephrology,Dezhou People’s Hospital of Shandong Province(Dezhou 253014,China)
Abstract:Objective: To explore the role of simvastatin in the treatment of colorectal cancer(CRC).Methods: Measure the serum levels of both IL-6 and IL-8 in CRC patients than in healthy volunteers with ELSA;compare the expression of IL-8 and IL-6 in tissue samples of tumor and adjacent normal colon mucosa obtained from patients with advanced(CRC) with RT-PCR;Measure the serum levels of both IL-6 and IL-8 in CRC patients after treatment with simvastatin(80 mg/day for 14 days)and in supernatant of colorectal cancer-derived cell lines(HT-29 and Caco-2) treated with simvastatin.Results: The mean values of serum levels of both IL-6 and IL-8 were significantly higher in CRC patients than in healthy volunteers(P〈0.05),The analysis of mRNAs expression for these proinflammatory cytokines determined by RT-PCR showed a higher level of IL-8-mRNA in tumor tissue than in normal mucosa(P〈0.05),while IL-6 was similarly expressed in tumor and normal tissue(P〉0.05).Treatment of CRC with simvastatin(80 mg/day for 14 days) led to a significant decrease of serum IL-6(P〈0.05),while the IL-8 level was less affected(P〉0.05).The in vitro experiments on colorectal cancer-derived cell lines(HT-29 and Caco-2) demonstrated that application of simvastatin decreased generation of both IL-6 and IL-8(P〈0.05).Conclusion: Simvastatin therapy results in a decrease in serum level of IL-6 in CRC,and simvastatin inhibits release of IL-8 and IL-6 from colorectal cell lines.
Keywords:Simvastatin Colorectal neoplasams IL-6   IL-8
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号